" class="no-js "lang="en-US"> Lung Cancer Archives - Medtech Alert
Monday, November 11, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

FluoGuide Announces Positive Topline Results from Phase IIa Trial of FG001 in Lung Cancer

FluoGuide, a Danish biotech company that pioneers precision cancer surgery, is pleased to announce positive […]

Genprex Receives Approval to Advance Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer […]

Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with Non-Small Cell Lung Cancer

Scorpion Therapeutics, a pioneering oncology company redefining the frontier of precision medicine through its Precision […]

Lantern Pharma Announces First Patient Dosed in Study for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

Lantern Pharma, a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning […]

VITRAC Therapeutics Initiates a Phase 1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

VITRAC Therapeutics initiated a Phase 1 Study of VIC-1911 as monotherapy and in combination with […]

ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo has announced that the European Medicines Agency (EMA) has validated the Type II […]

XtalPi and EDDC Collaborate in AI-empowered Drug Discovery Program for Non-Small Cell Lung Cancer

XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, has announced […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more